<DOC>
	<DOCNO>NCT02169479</DOCNO>
	<brief_summary>To investigate effect three single oral dos BIA 9-1067 ( 25 mg , 50 mg 100 mg ) levodopa pharmacokinetics administer combination single-dose immediate-release levodopa/carbidopa 100/25 mg ( Sinemet® 100/25 )</brief_summary>
	<brief_title>Pharmacokinetic-pharmacodynamic Interaction Between Each Three Diferente Single Doses BIA 9-1067 Single-dose Immediate-release 100/25 mg Levodopa/Carbidopa</brief_title>
	<detailed_description>Single centre , double-blind , randomize , placebo-controlled , crossover study four consecutive single-dose treatment period . The washout period dose least 14 day . On treatment period , completion pre-dose assessment , BIA 9-1067/Placebo administer concomitantly dose Sinemet® 100/25 ; post-dose assessment complete subject discharge 72 h post-dose . Subjects attend four treatment period receive different dose BIA 9-1067 ( 25 mg , 50 mg 100 mg ) placebo treatment period .</detailed_description>
	<mesh_term>Parkinson Disease</mesh_term>
	<mesh_term>Opicapone</mesh_term>
	<mesh_term>Carbidopa , levodopa drug combination</mesh_term>
	<mesh_term>Carbidopa</mesh_term>
	<mesh_term>Levodopa</mesh_term>
	<criteria>1 . Availability entire study period willingness adhere protocol requirement evidence informed consent form ( ICF ) duly read , sign date volunteer prior participation study . 2 . Male volunteer . 3 . Volunteers least 18 year age old 45 year . 4 . Volunteers body mass index ( BMI ) great equal 19 30 kg/m2 . 5 . Volunteers non exsmokers . An exsmoker define someone completely stop smoke least 12 month day 1 study . 6 . Volunteers healthy determine prestudy ( screen ) medical history , physical examination , vital sign , complete neurological examination 12lead ECG . 7 . Volunteers clinical laboratory test result judge clinically acceptable ( within laboratory 's state normal range ; within range , must without clinical significance ) screen admission first treatment period . 8 . Volunteers negative test hepatitis B surface antigen ( HBsAg ) , antihepatitis C antibody ( HCV Ab ) , Human immunodeficiency viruses 1 2 antibody ( HIV1 HIV2 Ab ) screening . 9 . Volunteers negative screen ethyl alcohol drug abuse screen . 10 . Due unknown risk potential harm unborn fetus , sexually active men must agree use medically acceptable form contraception throughout study . 1 . Volunteers conform inclusion criterion , case 2 . Volunteers clinically relevant surgical history . 3 . Volunteers clinically relevant family history . 4 . Volunteers history relevant atopy . 5 . Volunteers significant infection know inflammatory process screen first admission . 6 . Volunteers acute gastrointestinal symptom time screen first admission ( e.g. , nausea , vomit , diarrhoea , heartburn ) . 7 . Volunteers vegetarian , vegan medical dietary restriction . 8 . Volunteers communicate reliably investigator . 9 . Volunteers unlikely cooperate requirement study . 10 . Significant history hypersensitivity BIA 91067 , tolcapone , entacapone , levodopa , carbidopa relate product ( include excipients formulation ) well severe hypersensitivity reaction ( like angioedema ) drug . 11 . Presence significant gastrointestinal , liver kidney disease , condition know interfere absorption , distribution , metabolism excretion drug know potentiate predispose undesired effect . 12 . History significant gastrointestinal , liver kidney disease may affect drug bioavailability . 13 . Presence history significant cardiovascular , pulmonary , hematologic , neurologic , psychiatric , lymphatic , musculoskeletal , genitourinary , endocrine , immunologic , dermatologic connective tissue disease . 14 . Suicidal tendency , history disposition seizure , state confusion , clinically relevant psychiatric disease . 15 . Presence significant heart disease disorder accord ECG . 16 . Presence suspicious undiagnosed skin lesion history melanoma . 17 . Previous history Neuroleptic Malignant Syndrome ( NMS ) and/or nontraumatic rhabdomyolysis . 18 . Presence history significant glaucoma . 19 . Use prescription medication include MAO inhibitor within 28 day day 1 study . 20 . Use overthecounter ( OTC ) product within 7 day day 1 study . 21 . Maintenance therapy drug , significant history drug dependency ( drug abuse ) alcohol abuse ( &gt; 3 unit alcohol per day , intake excessive alcohol , acute chronic ) . 22 . Any clinically significant illness previous 28 day day 1 study . 23 . Use enzymemodifying drug , include strong inhibitor cytochrome P450 ( CYP ) enzymes ( cimetidine , fluoxetine , quinidine , erythromycin , ciprofloxacin , fluconazole , ketoconazole , diltiazem HIV antiviral ) strong inducer CYP enzyme ( barbiturate , carbamazepine , glucocorticoid , phenytoin rifampin ) , previous 28 day day 1 study . 24 . Volunteers take Investigational Product ( another clinical trial ) donate 50 mL blood previous 28 day day 1 study . 25 . Poor motivation , intellectual problem likely limit validity consent participate study limit ability comply protocol requirement inability cooperate adequately , inability understand observe instruction physician . 26 . Donation 500 mL blood ( Canadian Blood Services , HemaQuebec , clinical study , etc . ) previous 56 day day 1 study . 27 . Positive urine screen ethyl alcohol drug abuse admission treatment period . 28 . Any history tuberculosis and/or prophylaxis tuberculosis . 29 . Positive result HIV , HBsAg antiHCV test . 30 . Participation previous clinical study BIA 91067 within 84 day day 1 study .</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>July 2015</verification_date>
	<keyword>Parkinson 's disease ( PD )</keyword>
	<keyword>Opicapone</keyword>
	<keyword>BIA 9-1067</keyword>
</DOC>